MTOR and hepatocellular carcinoma: The phase II study EVOLVE-1 did not demonstrate any benefit of the mTOR inhibitor everolimus on the treatment of advanced HCC, and tumor heterogeneity was suggested as a possible explanation for the poor performance of targeted therapies (30).